
News|Articles|September 14, 2011
More Hematology Letters Link
Advertisement
More Letters
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
3
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5